Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Innoviva Inc (INVA)
NASDAQ:INVA
Innoviva (INVA) Stock Price & Analysis
272 Followers
INVA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.32 - $16.87
Previous Close$14.48
Volume636.37K
Average Volume (3M)672.04K
Market Cap
$928.81M
Enterprise Value$1.17B
Total Cash (Recent Filing)$193.51M
Total Debt (Recent Filing)$446.23M
Price to Earnings (P/E)6.6
Beta0.39
Next Earnings
May 01, 2024EPS Estimate
$0.17Last Dividend Ex-Date
Sep 08, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)2.18
Shares Outstanding63,227,333
10 Day Avg. Volume518,615
30 Day Avg. Volume672,045
Standard Deviation0.09
R-Squared0.11
Alpha-0.00140
Financial Highlights & Ratios
Price to Book (P/B)2.14
Price to Sales (P/S)2.76
Price to Cash Flow (P/CF)6.90
P/FCF Ratio5.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.00
Enterprise Value/Gross Profit3.78
Enterprise Value/Ebitda6.74
Forecast
1Y Price Target
$15.00Price Target Upside2.11% Upside
Rating ConsensusHold
Number of Analyst Covering1
Innoviva News
PremiumPre-Earnings
Is INVA a Buy, Before Earnings?
Ownership Overview
28.89% Insiders
33.53% Mutual Funds
35.02% Other Institutional Investors
2.56% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INVA FAQ
What was Innoviva Inc’s price range in the past 12 months?
Innoviva Inc lowest stock price was $11.32 and its highest was $16.86 in the past 12 months.
What is Innoviva Inc’s market cap?
Currently, no data Available
When is Innoviva Inc’s upcoming earnings report date?
Innoviva Inc’s upcoming earnings report date is May 01, 2024 which is in 12 days.
How were Innoviva Inc’s earnings last quarter?
Innoviva Inc released its earnings results on Feb 29, 2024. The company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.53.
Is Innoviva Inc overvalued?
According to Wall Street analysts Innoviva Inc’s price is currently Undervalued.
Does Innoviva Inc pay dividends?
Innoviva Inc pays a Semiannually dividend of $0.25 which represents an annual dividend yield of N/A. See more information on Innoviva Inc dividends here
What is Innoviva Inc’s EPS estimate?
Innoviva Inc’s EPS estimate is $0.17.
How many shares outstanding does Innoviva Inc have?
Innoviva Inc has 63,227,333 shares outstanding.
What happened to Innoviva Inc’s price movement after its last earnings report?
Innoviva Inc reported an EPS of $0.76 in its last earnings report, beating expectations of $0.23. Following the earnings report the stock price went down -0.262%.
Which hedge fund is a major shareholder of Innoviva Inc?
Among the largest hedge funds holding Innoviva Inc’s share is Hussman Strategic Advisors Inc. It holds Innoviva Inc’s shares valued at 2M.
---
Innoviva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$15.00 (2.11% Upside)
$15.00 (2.11% Upside)
Blogger Sentiment
Neutral
INVA Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 127.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.92%
12-Months-Change
Fundamentals
Return on Equity
28.97%
Trailing 12-Months
Asset Growth
0.98%
Trailing 12-Months
Company Description
Innoviva Inc
Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
---
INVA Stock 12 Months Forecast
Average Price Target
$15.00
▲(2.11% Upside)
Technical Analysis
Best Analysts Covering INVA
1 Year
1 Year Success Rate
3/4 ratings generated profit
1 Year Average Return
+10.78%
reiterated a buy rating 12 months ago
Copying Constantine Davides's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +10.78% per trade.
---